Conestat alfa

Drug Profile

Conestat alfa

Alternative Names: Human C1 esterase inhibitor - Pharming; Recombinant human C1 esterase inhibitor - Pharming; rhC1INH; Rhucin; Ruconest

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pharming Group NV
  • Class Complement C1 inactivator proteins; Immunotherapies; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Capillary leak syndrome; Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase II Acute kidney injury
  • Preclinical Delayed graft function; Reperfusion injury
  • Discontinued Renal transplant rejection

Most Recent Events

  • 06 Mar 2017 Updated efficacy data from a phase II trial in Hereditary angioedema presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2017)
  • 16 Jan 2017 The European commission amends Marketing authorisation of conestat alfa to include self-administration for the treatment of Hereditary angioedema in European Union
  • 01 Jan 2017 Phase-II clinical trials in Acute kidney injury (Prevention) in Switzerland (IV) (NCT02869347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top